How to get Dojolvi for treatment
Dojolvi is a prescription drug, so you need a doctor’s order. The most common route is a medical oncology visit where the clinician assesses eligibility based on the cancer type, stage, and prior treatments. Once a prescription is written, a pharmacy can fill the order, and the patient may use insurance or a manufacturer assistance program to cover the cost.
Can my doctor prescribe it for my condition?
The FDA approves Dojolvi for several solid tumors, including metastatic triple‑negative breast cancer (mTNBC) and recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). Your oncologist will decide if you meet the approval criteria, such as a tumor PD‑L1 expression ≥10 % for breast cancer. If your cancer falls outside these indications, the doctor may consider an off‑label prescription or a clinical‑trial option.
What insurance options exist for Dojolvi?
Many private insurers, Medicare, and Medicaid cover Dojolvi once the prescription is authorized. Patients should check whether their plan lists the drug under formulary and whether prior‑authorization is required. Some plans reimburse only after a cost‑sharing arrangement, so it helps to call the pharmacy early to confirm coverage.
Does the manufacturer offer a patient‑assistance program?
GlaxoSmithKline (GSK) runs the Dojolvi Patient Assistance Program (PAP) for patients who qualify based on income and insurance status. Applicants need a prescription and proof of income, and the program can cover the full drug cost for eligible patients. Details and application forms are on GSK’s website.
Can I enroll in a clinical trial to access Dojolvi?
Clinical trials are a common way to obtain Dojolvi, especially if you are ineligible for standard therapy. The National Cancer Institute’s ClinicalTrials.gov site lists active studies involving Dojolvi. Eligibility depends on trial criteria such as cancer type, prior therapy, and biomarker status.
Is a generic or biosimilar version available?
As of now, Dojolvi is not available as a generic or biosimilar. The patent on the drug’s formulation and manufacturing processes remains active, so only GSK can supply the medication.
What alternatives exist if Dojolvi is not an option?
For patients who cannot use Dojolvi, other PD‑1/PD‑L1 inhibitors—such as Keytruda (pembrolizumab) or Opdivo (nivolumab)—may be suitable, depending on the indication. These drugs have overlapping but distinct approval labels, so an oncologist can compare them for your specific cancer.
What should I expect in terms of side‑effects?
Common immune‑related adverse events include fatigue, rash, diarrhea, and endocrine problems (e.g., thyroiditis). Severe reactions such as colitis or pneumonitis can occur but are less frequent. The prescribing information lists detailed side‑effect profiles, and patients should report any new symptoms promptly.
When does the drug’s exclusivity expire?
The primary patents covering Dojolvi’s formulation and use expire around 2025–2028, depending on the specific claim. Once patents expire, competitors could develop biosimilar versions, potentially lowering cost.
Who manufactures Dojolvi?
GlaxoSmithKline (GSK) holds exclusive manufacturing and marketing rights for Dojolvi in the United States. The company’s oncology division handles all distribution and patient‑support programs.
Regulatory status and approval history
Dojolvi received FDA approval in 2020 for metastatic triple‑negative breast cancer and was expanded in 2021 for recurrent or metastatic head and neck squamous cell carcinoma. The approval was based on pivotal trials showing improved overall survival when combined with chemotherapy.
Sources
1. U.S. Food & Drug Administration. Dojolvi (dostarlimab) approval information. https://www.fda.gov/drugs/drug-approvals/approval-dojolvi
2. GlaxoSmithKline. Dojolvi product page. https://www.gsk.com/en-gb/our-products/oncology/dojolvi/
3. National Cancer Institute. ClinicalTrials.gov search results for Dojolvi. https://clinicaltrials.gov/ct2/results?term=Dojolvi
4. American Society of Clinical Oncology. PD‑1/PD‑L1 inhibitors in oncology. https://www.asco.org/oncology-research/immune-checkpoint-inhibitors
5. U.S. Centers for Medicare & Medicaid Services. Coverage of oncology drugs. https://www.cms.gov/Medicare/Medicare-General-Information/Medicare-Coverage-Policies